1. UK Health Tech – Innovation Showcase

2. Introduction
Manchester based SME, established by management buyout in November 2013
VC Funding £1.2 M loan notes plus £500 K cash
Now a leading molecular diagnostics manufacturer and developer with proprietary technology and knowhow
Suite of innovative in vitro diagnostic CE marked products
Global market leading products in CFTR and Trisomy
Products manufactured within an ISO accredited quality system to ensure optimal performance in the customer’s own laboratory
Committed to providing new innovative diagnostic solutions through global collaborations
In 2018 we are a company of 33 people exporting to approx. 50 markets, debts free, with revenues of circa £3.5 M and EBITDA of £1.2 M

3. Future Plans CDx Growth Vision \ Product Pipeline
Pharmaceutical Partners
Genetics Customers
Diagnostic Partners
Diagnostics
Bioinformatics Solutions
Companion Diagnostics
PCR CE Technology
Bioinformatics
NGS Technology
Product Pipeline
Product Development
Products
CRO Partners
CDx Growth Vision
To become a global leading provider of Companion diagnostics in order to enable a personalised medicine approach for patients, whilst reduce cost burden to international healthcare systems.
Direct expansion of Manchester Team
Partnering
Acquisition

4. Our market Current products reaching market saturation
Traditional genetic diagnostics market is changing
Focus from stand alone diagnostics is moving to personalised healthcare and companion diagnostics
As an industry our innovations must support market needs
Market driven by stagnated resources and an aging population with increasing expectations for a better standard of care
Elucigene are committed to bring to market CDx products that increase standards of patient care and better utilise stretched resources
Our innovations will bring us closer to our colleagues in pharmaceuticals
Increasing payer expectation that drugs will come to market with a CDx if possible and appropriate
Need to innovate our business model as well as our products
For most SMEs partnering will be a key consideration for sucess

5. Oncology
Oncology
Rheumatology
5-FU is a toxic component of 2 M chemotherapy regimes each year
Used in numerous cancer treatments – component of circa. 60 drugs on the market
Defective DYPD enzyme activity results in 10 to 15 % adverse reactions and 1 % lethality
Currently patient roulette is standard practice
Genetic susceptibility screening is now possible, and 2018 sees guidance in place
No CE IVD on the market to perform such screening
Elucigene DYDP launches Spring 2019
Enables susceptibility screening in 4 hours at low cost – Circa £35.00 per test
Susceptible individuals are placed on reduced or alternative therapy

6. Rheumatology
Oncology
Rheumatology
Rituximab (MabThera, Rocej) – Monoclonal used in combination with methotrexate in the treatment of patients with Rheumatoid Arthritis
Directed against B cells called CD-20 involved in the inflammatory process
2nd line treatment of patients non-responsive to disease-modifying antirheumatic drugs (DMARDs) such as anti-TNF drugs such as (Adalimumab, Etanercept, Infliximab)
Not all patients will respond to Rituximab, resulting in 6 months prolonged inadequate treatment at the cost of £3500 plus to the NHS (Higher in other markets)
Elucigene £700 K Eurostars Collaboration with TubaScan and ClinicaGenome to produce a predictive genetic screening tool for patients to inform likely response Rituximab
Patients characterised by a profile of 8 mRNA SNPs
Patients likely to be unresponsive are offered alternative therapy approaches such as Abatacept

7. Innovation Innovation is not always technology led
Elucigene utilise existing technologies to transform patient pathways
Partnering is key to success
Diagnostics Manufacturers
Funding
Contract Research and Clinical Trial Organisations
Academic Institutes
Pharmaceuticals
Health Care Providers (NHS)